Merck & Company MRK

$144.30 +0.49 (0.34%)

Valuation

Market cap
354,804,000,000
Revenue TTM
$65,011,000,000
Net income TTM
$18,254,000,000
PE ratio
45.27
Forward PE
52.62
Profit margin
28.08%
Debt to equity
1.22

Trading

Volume
9,661,800
Avg volume
10,079,544
Day's range
$142.73 – $144.35
Shares out
2,467,172,000
Stochastic %K
14%
Beta
0.21
Analysts
Strong Sell
Price target
$156.59

Price

Company profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th...

Show more

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
908 740 4000
Website
https://www.merck.com
Address
126 East Lincoln Avenue, Rahway, United States

Latest news

Stocktwits

Kingjake26 Oct 3, 4:27 PM
$CADL Better than Keytruda. This coming from the KOL mouth that predicted Keytruda would be game Changing. Now he says CAN-2409 is what they have been waiting for the last 20 years. $MRNA $XBI Listen to AUA. Listen from 17 minute mark and rest of call. Don’t miss out. $MRK https://edge.media-server.com/mmc/p/9fcro3ze/ Turning "Cold" Tumors "Hot": Cancers like prostate cancer are historically "cold," meaning they naturally suppress the immune system and don't respond well to immunotherapy drugs like Keytruda. A high abscopal effect would essentially act as an in-vivo vaccine, forcing the immune system to recognize the prostate cancer cells and attack them body-wide.
1 replies
BreakoutsHappen Oct 3, 4:20 AM
Breakouts Watchlist of the Week (Oct 5–9): 4 Mega Caps Before Earnings Season Why the EP9 SOS scanner filled up with mega caps this week. The character of the list changed. For 3 weeks the scanners were producing small caps with violent momentum — biotechs, regional banks, crypto-linked brokers. This week the EP9 SOS scanner returned 4 names with a combined market value above $8 trillion, and 1 of them also cleared the Reversal Bullish scanner on the same session. When money moves up the capitalization ladder it usually means it wants liquidity more than upside, and that is worth noticing in the week the Q3 reporting season opens. https://breakoutshappen.com/stock-news/breakouts-watchlist-of-the-week-oct-5-9-4-mega-caps-before-earnings-season-briefing $MRK $AAPL $XOM $TSM
0 replies
IndyOne Oct 3, 3:18 AM
$MRK August 19th shine wearing off a bit.
0 replies
Outcomes Oct 2, 11:03 PM
$IBRX $MRNA $MRK $PFE $JNJ …..tip of the iceberg https://open.substack.com/pub/aaronsiri/p/recap-of-some-of-the-lawsuits-petitions?r=re3i2&utm_medium=ios
1 replies
Outcomes Oct 2, 8:43 PM
$IBRX $MRNA $MRK $PFE $JNJ ....'gene therapy'...hard pass. mRNA BAD. I'll prefer ANKTIVA please, thank you. https://x.com/robinmonotti/status/2090353470247202938?s=20
2 replies
Diefreeandsell Oct 2, 6:01 PM
$IBRX Well now that lunch is over we can continue and just need $XBI to start going GREEN into close. Maybe $MRK has that new Tice BCG mfr plant grand opening soon. RE VOLUME dropped off some but should recover soon. 21.31mil shares, +183% compared to typical volume of 7.53mil by 1:53 pm ET. High Volume alert! Typical daily volume is 12.28mil shares over the past 6 months.
1 replies
CN545 Oct 2, 4:46 PM
$MRK my goodness the fundamentals are ugly
0 replies
SparkyReturns Oct 2, 2:34 PM
$ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $IBRX $JNJ $MRK $BAX
3 replies